Efficacy and Safety of Nitazoxanide for the Treatment of Hospitalized Patients With Moderate COVID-19
Status:
Recruiting
Trial end date:
2020-07-31
Target enrollment:
Participant gender:
Summary
This is a proof of concept study to evaluate the efficacy of nitazoxanide (600 mg BID) to
treat hospitalized patients with moderate COVID-19.
Phase:
N/A
Details
Lead Sponsor:
Azidus Brasil
Collaborators:
Centro de Genomas - UNIFESP Emilio Ribas Institute of Infectious Diseases Farmoquimica S.A. Hospital Casa de Saúde - Vera Cruz - Campinas - SP - Brazil Hospital Vera Cruz